|
|
||||||||
*These authors contributed equally to this research.
From the Center for Neurological Diseases (Drs. ArboledaVelasquez, Medina, Martinez de Arrieta, and Villegas), Brigham and Womens HospitalHarvard Medical School; Pathology Department (Dr. Frosch) and Neurology Department (Dr. Slaugenhaupt), Massachusetts General HospitalHarvard Medical School; Department of Biostatistics (Dr. Betensky), Harvard School of Public Health, Boston, MA; Wilson Laboratory (Dr. Lebo), George Washington University, Washington, DC; Grupo de Neurociencias de Antioquia (Drs. Lopera, Gutierrez, and Vargas, E. Lopez, D. SepulvedaFalla, and J. Restrepo), and Grupo de Genetica de Poblaiciones, Mutacarciogenesis y Epidemiologica Genetica (Dr. ArcosBurgos and D. Rivera), Universidad de Antioquia, Medellin, Colombia.
Address correspondence and reprint requests to Dr. Kenneth Kosik, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Boston, MA 02115; e-mail: kosik{at}cnd.bwh.harvard.edu
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is caused by mutations in the notch3 epidermal growth factorlike repeats. A Colombian kindred carries a novel C455R mutation located in the predicted ligand-binding domain. Stroke occurred in the patients at an unusually early age (median age: 31 years) in comparison to the more frequent onset in the fourth decade of life in other CADASIL populations, including a second Colombian kindred with an R1031C mutation.
This article has been cited by other articles:
![]() |
M. Monet-Lepretre, B. Bardot, B. Lemaire, V. Domenga, O. Godin, M. Dichgans, E. Tournier-Lasserve, M. Cohen-Tannoudji, H. Chabriat, and A. Joutel Distinct phenotypic and functional features of CADASIL mutations in the Notch3 ligand binding domain Brain, June 1, 2009; 132(6): 1601 - 1612. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Mykkanen, M. Junna, K. Amberla, L. Bronge, H. Kaariainen, M. Poyhonen, H. Kalimo, and M. Viitanen Different Clinical Phenotypes in Monozygotic CADASIL Twins With a Novel NOTCH3 Mutation Stroke, June 1, 2009; 40(6): 2215 - 2218. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Brass, E. E. Smith, J. F. Arboleda-Velasquez, W. A. Copen, and M. P. Frosch Case 12-2009 -- A 46-Year-Old Man with Migraine, Aphasia, and Hemiparesis and Similarly Affected Family Members N. Engl. J. Med., April 16, 2009; 360(16): 1656 - 1665. [Full Text] [PDF] |
||||
![]() |
J. F. Arboleda-Velasquez, R. Rampal, E. Fung, D. C. Darland, M. Liu, M. C. Martinez, C. P. Donahue, M. F. Navarro-Gonzalez, P. Libby, P. A. D'Amore, et al. CADASIL mutations impair Notch3 glycosylation by Fringe Hum. Mol. Genet., June 15, 2005; 14(12): 1631 - 1639. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Opherk, N. Peters, J. Herzog, R. Luedtke, and M. Dichgans Long-term prognosis and causes of death in CADASIL: a retrospective study in 411 patients Brain, November 1, 2004; 127(11): 2533 - 2539. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Singhal, S. Bevan, T. Barrick, P. Rich, and H. S. Markus The influence of genetic and cardiovascular risk factors on the CADASIL phenotype Brain, September 1, 2004; 127(9): 2031 - 2038. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |